In yesterday’s Wall Street session, Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares traded at $41.00, down -0.32% from the previous session.
As of this writing, 14 analysts cover Integra LifeSciences Holdings Corporation (NASDAQ:IART). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $65.00 and a low of $39.00, we find $44.00. Given the previous closing price of $41.13, this indicates a potential upside of 6.98 percent. IART stock price is now -10.47% away from the 50-day moving average and -20.08% away from the 200-day moving average. The market capitalization of the company currently stands at $3.31B.
There are 8 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $47.90 as their price target over the next twelve months.
In other news, De Witte Jan, President & CEO bought 7,792 shares of the company’s stock on Jun 01. The stock was bought for $299,986 at an average price of $38.50. Upon completion of the transaction, the President & CEO now directly owns 12,798 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 01, EVP, Chief Legal Officer & Sec Schwartz Eric bought 2,640 shares of the business’s stock. A total of $100,035 was incurred on buying the stock at an average price of $37.89. This leaves the insider owning 48,597 shares of the company worth $1.99 million. Insiders disposed of 200,585 shares of company stock worth roughly $8.22 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IART stock. A new stake in Integra LifeSciences Holdings Corporation shares was purchased by GLENMEDE TRUST CO NA during the first quarter worth $8,600,000. CAMPBELL & CO INVESTMENT ADVISER LLC invested $1,346,000 in shares of IART during the first quarter. In the first quarter, EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in Integra LifeSciences Holdings Corporation valued at approximately $1,265,000. HSBC HOLDINGS PLC acquired a new stake in IART for approximately $1,215,000. QUANTINNO CAPITAL MANAGEMENT LP purchased a new stake in IART valued at around $782,000 in the second quarter. In total, there are 384 active investors with 91.60% ownership of the company’s stock.
Monday morning saw Integra LifeSciences Holdings Corporation (NASDAQ: IART) opened at $40.87. During the past 12 months, Integra LifeSciences Holdings Corporation has had a low of $37.36 and a high of $60.69. As of last week, the company has a debt-to-equity ratio of 0.86, a current ratio of 3.60, and a quick ratio of 2.40. According to the stock market information, the enterprise value for the company is $4.64B, which is based on a 19.85 price-to-earnings ratio, a 3.31 price-to-earnings-growth ratio, and a beta of 1.17. The fifty day moving average price for IART is $45.79 and a two-hundred day moving average price translates $51.30 for the stock.
The latest earnings results from Integra LifeSciences Holdings Corporation (NASDAQ: IART) was released for Mar, 2023. According to the Medical Devices Company, earnings per share came in at $0.74, inline with analysts’ expectations of $0.74. This compares to $0.39 EPS in the same period last year. The net profit margin was 11.00% and return on equity was 10.00% for IART. The company reported revenue of $380.85 million for the quarter, compared to $376.64 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.12 percent. For the current quarter, analysts expect IART to generate $376.74M in revenue.
Integra LifeSciences Holdings Corporation(IART) Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
